Hutchmed
Hutchmed, officially known as Hutchison China MediTech Limited, is a prominent biopharmaceutical company headquartered in Hong Kong. Founded in 2016, Hutchmed has rapidly established itself as a leader in the oncology and immunology sectors, focusing on the discovery, development, and commercialisation of innovative therapies. With a strong operational presence in China and the United States, Hutchmed has achieved significant milestones, including the successful launch of its flagship products, which are designed to address unmet medical needs in cancer treatment. The company’s unique approach combines cutting-edge research with a deep understanding of local markets, positioning it favourably within the competitive biopharmaceutical landscape. Hutchmed's commitment to advancing healthcare solutions has garnered recognition, making it a notable player in the global biopharmaceutical industry.
DitchCarbon Score
How does Hutchmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hutchmed's score of 32 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hutchmed's reported carbon emissions
In 2023, Hutchmed reported total carbon emissions of approximately 78,772,000 kg CO2e. This figure includes 320,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 6,640,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. The majority of their emissions, about 71,812,000 kg CO2e, fall under Scope 3, which encompasses all other indirect emissions in the value chain. Notably, the largest contributors to Scope 3 emissions include purchased goods and services (approximately 58,103,089 kg CO2e) and upstream leased assets (about 4,236,908 kg CO2e). Hutchmed has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. However, the company is actively monitoring and reporting its emissions across all scopes, demonstrating a commitment to transparency in its climate impact. The absence of defined reduction targets suggests that while Hutchmed is aware of its emissions, it may still be in the early stages of developing a comprehensive climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 14,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 5,073,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 262,000 | 000,000 | 000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hutchmed is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
